FDA Approves Vasorum’s Celt ACD Plus Vascular Closure Device

Vasorum USA, a company focused on redefining vascular closure, has gained U.S. Food and Drug Administration (FDA) approval of its Celt ACD Plus system, which features Blood Signal technology.

Celt ACD Plus is a small-bore closure device designed for rapid arterial puncture closure after percutaneous catheter-based vascular procedures. The device is available in 5F, 6F, and 7F sizes.

Its mechanism of action reduces major vascular closure complications like bleeding, hematomas, and pseudoaneurysms. Vasorum said clinical data has shown significant reduction in time to hemostasis, ambulation, and discharge.

The newly approved, next-gen device provides a visual indicator for precise placement and closure, which is useful in cases where ultrasound imaging isn’t available.

The first commercial cases using Celt ACD Plus were completed at The Prime Vascular Institute by Joseph Ricotta, MD, MS, FACS, Founder and Program Director of the Vascular Surgery Fellowship at Florida Atlantic University School of Medicine.

“The Celt ACD Plus represents a significant advancement in vascular closure,” said Dr. Ricotta. “By providing a visual indicator for accurate deployment, it shortens the learning curve for new users and expands access to the Celt ACD technology. This is particularly beneficial in settings where ultrasound guidance may not be available, ensuring consistent, reliable closures across a broader range of clinical scenarios.”

“The FDA approval of Celt ACD Plus marks an exciting milestone for Vasorum and the physicians we serve,” said Vasorum USA VP of sales and marketing David Gunther. “By enhancing the safety and efficiency of arterial closure, we continue to build on our commitment to innovation and improving procedural outcomes for both physicians and patients.”